| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | entrectinib (Rozlytrek®) |
| Formulation | 100 mg and 200 mg capsule |
| Reference number | 4169 |
| Indication | As monotherapy indicated for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 29/06/2020 |
| NICE guidance | TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Commercial arrangement | PAS |